StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Rahul Sharma, JM Financial

BUYDr. Reddy's Laboratories Limited

byRahul Sharma, JM FinancialHorizon: NA (inferred Swing (≤2wk))23 Sept 2026via CNBC Awaaz.

Entry₹1,217.2Inferred
Target₹1,300
Total upside +6.80%
Stop loss₹1,180-3.06% risk
CMP₹1,211.23h ago
Active-0.49%+7.33%upside left 14d left
Follow Rahul Sharma for new calls(26% target hit, 46 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 3 other Swing calls on DRREDDYSee 255 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Sept, 8:05 pm IST
6 supporting1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·23 Sept · today

4 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · 2d ago

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·21 Sept · 2d ago

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre

BSE · Company Update·18 Sept · 5d ago

(opens in new tab)

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NewsGoogle News·10 Sept · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.